Study Shows Sequenom CMM's RetnaGene LDT Accurately Predicts Risk of Progression to Wet Form of AMD

     Study Shows Sequenom CMM's RetnaGene LDT Accurately Predicts Risk of
                        Progression to Wet Form of AMD

Results Evaluating Genetic Test Presented at AAO Annual Meeting

PR Newswire

SAN DIEGO, Nov. 12, 2012

SAN DIEGO, Nov. 12, 2012 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative diagnostic testing and genetic analysis
solutions, today announced its wholly-owned subsidiary, Sequenom Center for
Molecular Medicine (Sequenom CMM), presented results from a study of its
RetnaGene AMD laboratory-developed test to predict risk of disease progression
during the 2012 Joint Meeting of the American Academy of Ophthalmology and the
Asia-Pacific Academy of Ophthalmology in Chicago.

This Sequenom CMM laboratory-developed genetic test (LDT) combines patient
disease stage with patient genetic variation to evaluate the risk of a patient
with early or intermediate AMD to progress to advanced choroidal
neovascularization (CNV) disease within 2, 5, and 10 years. CNV is the most
common form of 'wet' advanced age-related macular degeneration (AMD), in which
new blood vessels in the eye leak fluid, compromising central vision. Advanced
disease impacts approximately 10 percent of AMD patients, but is associated
with 90 percent of vision loss in AMD.

The clinical validation of the laboratory test predicting progression to CNV
was conducted using patient DNA samples made available through the National
Eye Institute's Age-Related Eye Disease Study (AREDS). More than 2,000
patients were genotyped for 13 single nucleotide gene polymorphisms (SNPs) in
genes previously shown to be associated with CNV. Sequenom CMM compared the
predictive value of a phenotype model, based on the assessment of disease
grade currently used in clinical practice. The predictive model that combined
genotype with phenotype was found to be more accurate in predicting CNV
progression (AUC=0.96) than the phenotype model alone based on disease grade
(AUC=0.89), concluding that inclusion of the genotype assessment is more
effective in predicting CNV progression compared with phenotype alone.

"Physicians today rely on an assessment of patient disease stage to predict
the risk of progressing to CNV, and this genetic laboratory developed test
will help improve the accuracy of prediction by assessing individual risk
based on the genetic predisposition of the patient," said Allan T. Bombard,
M.D., Sequenom's Chief Medical Officer.

The study was conducted in compliance with the Coriell Cell Repositories
Institutional Review Board, in accordance with Department of Health and Human
Services (45 CFR Part 46). The dataset used for the analysis was obtained from
the National Eye Institute-Age-Related Eye Disease Study (NEI-AREDS) Genetic
Repository. Funding support for AREDS was provided by the National Eye
Institute grant N01-EY-0-2127, National Institutes of Health, Bethesda,

At the meeting: Paper 30031594: Combining Genotype and Phenotype to Predict
Progression to Choroidal Neovascularization (CNV) in Patients with AMD
(Presented Monday, November 12, 3:42 PM in S406B)

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

Sequenom CMM, LLC
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and
CLIA-certified molecular diagnostics laboratory, is developing a broad range
of laboratory-developed tests with a focus on prenatal and ophthalmic diseases
and conditions. These laboratory-developed tests provide beneficial patient
management options for obstetricians, geneticists, maternal fetal medicine
specialists, retinal specialists and ophthalmologists. Sequenom CMM is
changing the landscape in genetic disorder diagnostics using proprietary
cutting edge technologies.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth
in this press release are forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995, including statements regarding the benefits or expectations of Sequenom
CMM's genetic AMD test including the test's ability to help improve the
accuracy of predicting the risk of a patient progressing to CNV by assessing
individual risk based on the genetic predisposition of the patient, Sequenom's
commitment to improving healthcare through revolutionary genetic analysis
solutions, and Sequenom CMM changing the landscape in genetic disorder
diagnostics. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially, including
the risks and uncertainties associated with Sequenom's ability to develop and
commercialize new technologies and products and to scale up its operations to
meet increased product demand, particularly for new technologies and products
such as Sequenom CMM's prenatal and other diagnostics testing services,
Sequenom's ability to manage its existing cash resources or raise additional
cash resources, customer demand, Sequenom's ability to obtain payor
reimbursement and payment collection and the timing thereof, for Sequenom
CMM's diagnostic test services including the MaterniT21 PLUS LDT, Sequenom's
ability to convert to accrual accounting for its diagnostic test services
including the MaterniT21 PLUS LDT, competition, intellectual property
protection and intellectual property rights of others, government regulation
particularly with respect to diagnostic products and laboratory developed
tests, obtaining or maintaining regulatory approvals, ongoing litigation,
including patent litigation asserting infringement by our products or
challenging the validity of our patents, and other risks detailed from time to
time in Sequenom, Inc.'s most recent Quarterly Report on Securities and
Exchange Commission Form 10-Q and Annual Report on Securities and Exchange
Commission Form 10-K and other documents subsequently filed with or furnished
to the Securities and Exchange Commission. These forward-looking statements
are based on current information that may change and you are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date of this press release. All forward-looking statements are
qualified in their entirety by this cautionary statement, and Sequenom, Inc.
undertakes no obligation to revise or update any forward-looking statement to
reflect events or circumstances after the issuance of this press release.


SOURCE Sequenom, Inc.

Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., +1-858-202-9028,, Jakob Jakobsen, Media
Contact, Chandler Chicco Agency, +1-310-309-1003,
Press spacebar to pause and continue. Press esc to stop.